Source: Midwest AIDS Training + Education Center
Published October 12, 2017
On October 12, 2017 the FDA approved changed to the Sustiva (efavirenz) package insert to:
- Update information on hepatotoxicity in DOSAGE and ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS and Patient Information sections.
- Update CONTRAINDICATIONS and Patient Information sections with drug-drug interaction information on elbasvir and grazoprevir.
- Update DRUG INTERACTIONS, Table 5 with information about hepatitis C antiviral agents